Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 21c, Revenues Beat
November 9, 2020 7:36 AM ESTIntra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.79), $0.21 better than the analyst estimate of ($1.00). Revenue for the quarter came in at $7.37 million versus the consensus estimate of $5.86 million.
Our Company is in a strong position. CAPLYTA is approved for the treatment of... More
